CIK 0001178670 · Large accelerated filer
ALNYLAM PHARMACEUTICALS, INC.
Sign in to watch- Ticker
- ALNY
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 770602661
- Phone
- (617) 551-8200
- Business address
- 675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, 02142
- Former names
- ALNYLAM PHARMACEUTICALS INC
- Open-market buys, last 90 days
- $543,126
- in 2 filings
- Open-market sales, last 90 days
- $398,855
- in 1 filing
Net +$144,271. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-03-02 | Greenstreet Yvonne Chief Executive Officer | Sale | −424 | $328.71 | $139K | 100,255 |
| 2026-03-02 | Greenstreet Yvonne Chief Executive Officer | Sale | −722 | $329.71 | $238K | 99,533 |
| 2026-03-02 | Greenstreet Yvonne Chief Executive Officer | Sale | −346 | $330.85 | $114K | 99,187 |
| 2026-03-02 | Greenstreet Yvonne Chief Executive Officer | Sale | −399 | $331.93 | $132K | 98,788 |
| 2026-03-02 | Greenstreet Yvonne Chief Executive Officer | Sale | −160 | $332.64 | $53K | 98,628 |
| 2026-03-02 | Greenstreet Yvonne Chief Executive Officer | Grant or award · Stock Option (right to buy) | +30,425 | 30,425 | ||
| 2026-03-02 | Greenstreet Yvonne Chief Executive Officer | Grant or award · Stock Price Performance Stock Unit | +110,746 | 110,746 | ||
| 2026-02-27 | Greenstreet Yvonne Chief Executive Officer | Option exercise | +5,921 | 91,583 | ||
| 2026-02-27 | Greenstreet Yvonne Chief Executive Officer | Option exercise · Restricted Stock Units | −5,921 | 0 | ||
| 2026-02-27 | Poulton Jeffrey V. EVP, Chief Financial Officer | Option exercise | +1,908 | 61,710 | ||
| 2026-02-27 | Poulton Jeffrey V. EVP, Chief Financial Officer | Option exercise · Restricted Stock Units | −1,908 | 0 | ||
| 2026-02-27 | Tanguler Tolga EVP, Chief Commercial Officer | Option exercise | +1,666 | 33,435 | ||
| 2026-02-27 | Tanguler Tolga EVP, Chief Commercial Officer | Option exercise · Restricted Stock Units | −1,666 | 0 | ||
| 2026-02-27 | Garg Pushkal EVP Chief R&D | Option exercise 10b5-1 | +1,908 | 26,756 | ||
| 2026-02-27 | Garg Pushkal EVP Chief R&D | Sale 10b5-1 | −127 | $328.92 | $42K | 26,629 |
| 2026-02-27 | Garg Pushkal EVP Chief R&D | Sale 10b5-1 | −2,259 | $330.73 | $747K | 24,370 |
| 2026-02-27 | Garg Pushkal EVP Chief R&D | Sale 10b5-1 | −1,159 | $331.49 | $384K | 23,211 |
| 2026-02-27 | Garg Pushkal EVP Chief R&D | Sale 10b5-1 | −942 | $332.48 | $313K | 22,269 |
| 2026-02-27 | Garg Pushkal EVP Chief R&D | Sale 10b5-1 | −140 | $334.39 | $47K | 22,129 |
| 2026-02-27 | Garg Pushkal EVP Chief R&D | Option exercise · Restricted Stock Units 10b5-1 | −1,908 | 0 |
Page 9 of 41 · 816 trades